>北美 API 中间体市场，按类型（兽药中间体、制药 / 大宗药物中间体）、产品（溴化合物、O-苄基沙丁胺醇、半硫酸盐、环氧乙烷、比索洛尔碱、手性 PCBHP、非那敏碱、氯苯那敏碱、溴苯那敏碱、美吡拉敏/吡拉明碱、6-氨基-1,3-二甲基尿嘧啶、茶碱、乙酰茶碱、黄嘌呤、腈类、其他）、治疗类型（自身免疫性疾病、肿瘤学、代谢性疾病、眼科、心血管疾病、传染病、神经病学、呼吸系统疾病、皮肤病学、泌尿科、其他）、客户（直接用户 / 制药公司、贸易商 / 批发商 / 分销商、协会 / 政府机构 / 私人机构）、最终用户（API 制造商、成品产品制造商）、分销渠道（直接招标、零售、其他）、国家（美国、加拿大、墨西哥）行业趋势与预测（至 2028 年）
市场分析和见解：北美 API 中间体市场
北美 API 中间体市场预计将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，该市场的复合年增长率为 6.3%，预计到 2028 年将达到 134.911 亿美元。慢性病负担沉重和老龄化人口增加是预测期内推动市场需求的主要驱动因素。
活性药物成分是用于制造药品的物质或物质组合，当用于生产药品时，它们就成为活性药物成分。此类物质用于提供药理活性。最终的药物剂型是使用 API 和赋形剂配制的，但 API 是使用称为中间体的原材料配制的。API 中间体是在 API 过程中产生的一种材料。中间体是活性药物成分的副产品，具有与 API 相同的治疗活性。这些中间体还用于治疗各种慢性疾病，例如癌症、呼吸系统疾病和传染病等。
API 中间体是用作配制或生产活性药物成分的原材料的药剂或化合物。这些中间体经过精炼或分子变化形成最终 API。中间体的生产涉及不同的技术，例如胺化、烷氧基化、电化学、氢化、氢甲酰化、乙炔化学、光气化学和其他技术。
随着各种慢性疾病的发病率不断上升以及人口老龄化，API 中间体市场正在不断增长。此外，药物 API 及其中间体研究和开发的不断增加也是加速 API 中间体市场增长的其他因素。
API 中间体市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。
北美 API 中间体市场范围和市场规模
中间体市场根据类型、产品、治疗类型、客户、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据类型，API 中间体市场细分为兽药中间体、医药/原料药中间体。2021 年，由于成品生产对 API 的需求不断增加，以及各种疾病的流行率不断上升，需要继续生产药物，预计医药/原料药中间体将主导 API 中间体市场。
- 根据产品，API 中间体市场细分为溴化合物、O-苄基沙丁胺醇、半硫酸盐、环氧乙烷、比索洛尔碱、手性 PCBHP、苯那敏碱、氯苯那敏碱、溴苯那敏碱、美吡拉敏/吡拉明碱、6-氨基-1,3-二甲基尿嘧啶、茶碱、乙酰茶碱、黄嘌呤、腈类等。2021 年，腈类产品预计将在 API 中间体市场占据主导地位，因为该产品成本高，并且将继续研发创新 API。
- 根据治疗类型，API 中间体市场细分为自身免疫性疾病、肿瘤学、代谢疾病、眼科学、心血管疾病、传染病、神经病学、呼吸系统疾病、皮肤病学、泌尿科等。2021 年，心血管疾病领域预计将主导 API 中间体市场，因为心血管疾病是全球死亡的主要原因。
- 根据客户，API 中间体市场分为直接用户/制药公司、贸易商/批发商/分销商和协会/政府机构/私人机构。2021 年，直接用户/制药公司细分市场预计将主导 API 中间体市场，因为 API 制造商是中间体的主要和直接用户。合同制造的兴起也推动了市场的发展。
- 根据最终用户，API 中间体市场细分为API 制造商和成品制造商。2021 年，API 制造商细分市场在 API 中间体市场中占据主导地位，因为中间体是 API 的主要化学底物，可以进一步转化为 API。因此，API 制造商广泛使用中间体来降低制造成本。
- 根据分销渠道，API 中间体市场分为直接招标、零售和其他。2021 年，直接招标预计将主导 API 中间体市场，因为直接招标为采购商品提供了巨大的利润空间，并且直接招标具有竞争性的合同选择和顾问责任制。
API 中间体市场国家层面分析
对 API 中间体市场进行分析，并根据上述类型、产品、治疗类型、客户、最终用户和分销渠道提供市场规模信息。
北美 API 中间体市场报告涵盖的国家包括美国、墨西哥、加拿大。
美国引领着北美地区的增长，医药/原料药中间体领域在美国占据主导地位，因为美国是全球最大的活性药物成分生产国。由于政府加大对原料药生产的投入，加拿大成为增长最快的国家。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
关于药物 API 及其中间体的研究和开发以及疾病意识和教育的提高正在推动 API 中间体的市场增长
API 中间体市场还为您提供每个国家 API 中间体行业增长的详细市场分析，包括 API 中间体药物销售、API 中间体技术进步的影响以及监管环境的变化及其对 API 中间体市场的支持。数据涵盖 2010 年至 2019 年的历史时期。
竞争格局和 API 中间体市场份额分析
API 中间体市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对 API 中间体市场的关注有关。
经营北美 API 中间体的主要公司包括 Cambrex Corporation、AlzChem Group AG、Vasudha Pharma、安阳化工总公司、Sarex、Sandoo Pharmaceuticals and Chemicals Co., Ltd.、Atul Ltd、Sandoz International GmbH（Novartis AG 的子公司）、Aceto、Supriya Lifescience Ltd.、Vertellus、Sanofi、Divi's Laboratories Limited、AARTI INDUSTRIES LIMITED、Aurobindo Pharma、BASF SE 等。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。
全球范围内的许多产品发布和协议也由公司发起，这也加速了API中间体市场的发展。
例如，
- 2020 年 11 月，AlzChem Group AG 宣布扩大腈类化合物的生产，腈类化合物是该公司的中间体之一。该公司已决定将产量扩大 50%。该公司这样做的动机是为了满足药品和杀生物剂的需求。腈类化合物生产工厂基于气相技术，该技术已由公司工程师进行了优化和验证。此次扩张帮助该公司增强了其在中间体领域的增长，这将有助于他们提高生产能力。
- 2019 年 8 月，Cambrex Corporation 宣布已被 Permira Funds 收购，该公司的发展势头迅猛，已成为药物成分、中间体和最终产品的顶级合同开发和制造组织之一。该公司以每股 60 美元的现金价格被收购。该协议帮助该公司成为药物成分、中间体、分析服务方面的领先公司之一，这将增强公司的客户关系，有利于公司的发展。
市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在 API 中间体市场中的市场，这也为组织改进其 API 中间体产品提供了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA API INTERMEDIATES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET TYPE COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 CURRENT SCENARIO OF IMPORT AND EXPORT OF API INTERMEDIATE
4.2 TENTATIVE PRODUCTION AND OPERATIONAL COSTS CALCULATIONS WHICH WILL ULTIMATELY LEAD TO FEASIBILITY OF THE PRODUCT MANUFACTURING
4.2.1 TENTATIVE LAND REQUIREMENT FOR A SUBSTANTIAL PRODUCTION CAPACITY PLANT SET-UP
4.3 NORTH AMERICA API INTERMEDIATES MARKET: 3C ANALYSIS-CHINA EFFECT
4.3.1 THE U.S.-CHINA TRADE WAR
4.3.2 INDO-CHINA GEOPOLITICAL ISSUES
4.3.3 CHINESE SLOWDOWN DUE TO E&C OVER THE YEARS
4.3.4 CHINESE SLOWDOWN DUE TO COVID-19 (CORONAVIRUS)
4.4 COST ANALYSIS
4.5 ANALYSIS ON CHINA API INTERMEDIATES:
4.5.1 CONCLUSION:
4.6 PORTERS FIVE FORCES MODEL
4.7 PESTEL ANALYSIS
4.8 NORTH AMERICA API INTERMEDIATES MARKET: REGULATORY
4.8.1 THE U.S. REGULATORY GUIDANCE FOR NON-CLINICAL SAFETY EVALUATION OF API INTERMEDIATES
4.8.2 CANADA REGULATORY GUIDANCE FOR API INTERMEDIATES
4.8.3 EUROPE REGULATORY SCENARIO FOR API INTERMEDIATES
4.8.4 JAPAN REGULATORY FOR API INTERMEDIATES
4.8.5 MIDDLE EAST AND AFRICA REGULATORY FRAMEWORK FOR API INTERMEDIATES
5 NORTH AMERICA API INTERMEDIATES MARKET: CONCLUSION
5.1 TOP PRODUCTS AND THERAPEUTIC AREAS
5.2 ADDITIONAL
6 CUSTOMER SENTIMENTS/INCLINATION TOWARDS FINDING ALTERNATE VENDOR SOURCE
7 LIST OF API OR FORMULATION COMPANIES WITH API INTERMEDIATE:
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 HIGH BURDEN OF CHRONIC DISEASES
8.1.2 INCREASE IN AGING POPULATION
8.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING
8.1.4 INCREASING DISEASE AWARENESS AND EDUCATION
8.1.5 RESEARCH AND DEVELOPMENT REGARDING PHARMACEUTICAL API AND THEIR INTERMEDIATES
8.2 RESTRAINTS
8.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS
8.2.2 PRODUCT RECALLS
8.2.3 HIGH MANUFACTURING COST
8.2.4 STRINGENT GOVERNMENT REGULATIONS FOR API INTERMEDIATES
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
8.3.2 INCREASING HEALTHCARE EXPENDITURE
8.3.3 SOARING NUMBER OF API INTERMEDIATES MANUFACTURERS
8.3.4 RISE IN NUMBER OF CONTRACT MANUFACTURING ORGANIZATIONS (CMO) AND CONTRACT RESEARCH ORGANIZATIONS (CRO)
8.4 CHALLENGES
8.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19
8.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES
9 IMPACT OF COVID 19 ON NORTH AMERICA API INTERMEDIATES MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE
9.5 CONCLUSION
10 NORTH AMERICA API INTERMEDIATES MARKET, BY TYPE
10.1 OVERVIEW
10.2 PHARMACEUTICAL INTERMEDIATES/ BULK DRUG INTERMEDIATES
10.3 VETERINARY DRUG INTERMEDIATES
11 NORTH AMERICA API INTERMEDIATES MARKET, BY PRODUCT
11.1 OVERVIEW
11.2 NITRILES
11.3 BROMO COMPOUND
11.4 CHIRAL PCBHP
11.5 CHLORPHENIRAMINE BASE
11.6 BROMPHENIRAMINE BASE
11.7 PHENIRAMINE BASE
11.8 O-BENZYL SALBUTAMOL
11.9 BISOPROLOL BASE
11.1 HEMISULFATE
11.11 OXIRANE
11.12 MEPYRAMINE/PYRILAMINE BASE
11.13 THEOFYLLINE
11.14 ACEFYLLINE
11.15 XANTHINE
11.16 6-AMINO-1,3-DIMETHYL URACIL
11.17 OTHERS
12 NORTH AMERICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE
12.1 OVERVIEW
12.2 CARDIOVASCULAR DISEASES
12.3 METABOLIC DISEASES
12.4 INFECTIOUS DISEASES
12.5 RESPIRATORY DISEASES
12.6 NEUROLOGY
12.7 ONCOLOGY
12.8 AUTOIMMUNE DISEASE
12.9 DERMATOLOGY
12.1 OPHTHALMOLOGY
12.11 UROLOGY
12.12 OTHERS
13 NORTH AMERICA API INTERMEDIATES MARKET, BY CUSTOMERS
13.1 OVERVIEW
13.2 DIRECT USERS/PHARMA COMPANIES
13.3 TRADERS/WHOLESALERS/DISTRIBUTORS
13.4 ASSOCIATIONS/GOVT. INSTITUTIONS/PVT INSTITUTIONS
14 NORTH AMERICA API INTERMEDIATES MARKET, BY END USER
14.1 OVERVIEW
14.2 API MANUFACTURER
14.3 FINISHED PRODUCT MANUFACTURER
15 NORTH AMERICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALE
15.4 OTHERS
16 NORTH AMERICA API INTERMEDIATES MARKET BY GEOGRAPHY
16.1 NORTH AMERICA
16.1.1 U.S
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA API INTERMEDIATES MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 AUROBINDO PHARMA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 DIVI’S LABORATORIES LIMITED
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 BASF SE
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 CAMBRIX CORPORATION
19.4.1 COMPANY SNAPSHOT
19.4.2 COMPANY SHARE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENTS
19.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 ACETO
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 HIKAL LTD.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 ALZCHEM GROUP AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 VERTELLUS
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT CATEGORIES
19.9.3 RECENT DEVELOPMENTS
19.1 SANOFI
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 ATUL LTD
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 AARTI INDUSTRIES LIMITED
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 VASUDHA PHARMA
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 ANYANG GENERAL CHEMICAL CO., LTD.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 DISHMAN CARBOGEN AMICS LTD
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 GANESH-GROUP
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENTS
19.17 LEVACHEM COMPANY LIMITED
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 SANDOO PHARMACEUTICALS AND CHEMICALS CO., LTD.
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 SAREX
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 SUPRIYA LIFESCIENCE LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS INTERMEDIATES: CUSTOMIZATION (COUNTRIES INVOLVED IN IMPORT & EXPORT)
TABLE 2 PERCENTAGE BREAK UP OF COST
TABLE 3 TENTATIVE LAND REQUIREMENT
TABLE 4 PERCENTAGE BREAK UP OF PLANT AREA
TABLE 5 TABLE: 1 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS INTERMEDIATES: LIST OF API OR FORMULATION COMPANIES WITH API INTERMEDIATE
TABLE 6 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
TABLE 7 MARKET PLAYERS OF API INTERMEDIATES
TABLE 8 SALES DATA OF API INTERMEDIATES FOR 2019/2020
TABLE 9 NORTH AMERICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA PHARMACEUTICAL INTERMEDIATES/ BULK DRUG INTERMEDIATES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA VETERINARY DRUG INTERMEDIATES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA NITRILES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA BROMO COMPOUND IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA CHIRAL PCBHP IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA CHLORPHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA BROMPHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA PHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA O-BENZYL SALBUTAMOL IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA BISOPROLOL BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA HEMISULFATE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA OXIRANE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA MEPYRAMINE/PYRILAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA THEOFYLLINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA ACEFYLLINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA XANTHINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA 6-AMINO-1, 3-DIMETHYL URACIL IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA OTHERS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA CARDIOVASCULAR DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 31 NORTH AMERICA METABOLIC DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICAINFECTIOUS DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA RESPIRATORY DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA NEUROLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA ONCOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA AUTOIMMUNE DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA DERMATOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA OPHTHALMOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA UROLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA OTHERS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA DIRECT USERS/PHARMA COMPANIES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA TRADERS/WHOLESALERS/DISTRIBUTORS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA ASSOCIATIONS/GOVT. INSTITUTIONS/PVT INSTITUTIONSIN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA API MANUFACTURER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA FINISHED PRODUCT MANUFACTURER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA DIRECT TENDER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA RETAIL SALES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA OTHERSIN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA API INTERMEDIATES MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 53 NORTH AMERICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 59 U.S API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 U.S API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 61 U.S API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 62 U.S API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 63 U.S API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 U.S API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 65 CANADA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 CANADA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 67 CANADA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 68 CANADA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 69 CANADA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 CANADA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 MEXICO API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 MEXICO API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 73 MEXICO API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 74 MEXICO API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 75 MEXICO API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 76 MEXICO API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA API INTERMEDIATES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA API INTERMEDIATES MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA API INTERMEDIATES MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA API INTERMEDIATES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA API INTERMEDIATES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA API INTERMEDIATES MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA API INTERMEDIATES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA API INTERMEDIATES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA API INTERMEDIATES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA API INTERMEDIATES MARKET: MARKET TYPE COVERAGE GRID
FIGURE 11 NORTH AMERICA API INTERMEDIATES MARKET: SEGMENTATION
FIGURE 12 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING IS DRIVING THE NORTH AMERICA API INTERMEDIATES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 PHARMACEUTICAL / BULK DRUG INTERMEDIATES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA API INTERMEDIATES MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA API INTERMEDIATES MARKET
FIGURE 15 TOP 5 COUNTRIES FOR NUMBER OF PEOPLE AGED 20 TO 79 SUFFERING FROM DIABETES IN 2019
FIGURE 16 ESTIMATED NUMBER OF DIFFERENT TYPES OF CANCERS IN FEMALE POPULATION IN 2020
FIGURE 17 ESTIMATED NUMBER OF DIFFERENT TYPES OF CANCERS IN MALE POPULATION IN 2020
FIGURE 18 NORTH AMERICA CAUSES OF DEATHS WITH THE CHRONIC DISEASES
FIGURE 19 NUMBER OF PERSON AGED 60 YEARS OR OVER BY REGIONS IN 2020 (IN MILLIONS)
FIGURE 20 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 21 NORTH AMERICA API INTERMEDIATES MARKET: BY TYPE, 2021
FIGURE 22 NORTH AMERICA API INTERMEDIATES MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 23 NORTH AMERICA API INTERMEDIATES MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 24 NORTH AMERICA API INTERMEDIATES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA API INTERMEDIATES MARKET: BY PRODUCT, 2021
FIGURE 26 NORTH AMERICA API INTERMEDIATES MARKET: BY PRODUCT, 2019-2028 (USD MILLION)
FIGURE 27 NORTH AMERICA API INTERMEDIATES MARKET: BY PRODUCT, CAGR(2021-2028)
FIGURE 28 NORTH AMERICA API INTERMEDIATES MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 29 NORTH AMERICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, 2021
FIGURE 30 NORTH AMERICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
FIGURE 31 NORTH AMERICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, CAGR (2021-2028)
FIGURE 32 NORTH AMERICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, LIFELINE CURVE
FIGURE 33 NORTH AMERICA API INTERMEDIATES MARKET: BY CUSTOMERS, 2021
FIGURE 34 NORTH AMERICA API INTERMEDIATES MARKET: BY CUSTOMERS, 2019-2028 (USD MILLION)
FIGURE 35 NORTH AMERICA API INTERMEDIATES MARKET: BY CUSTOMERS, CAGR (2021-2028)
FIGURE 36 NORTH AMERICA API INTERMEDIATES MARKET: BY CUSTOMERS, LIFELINE CURVE
FIGURE 37 NORTH AMERICA API INTERMEDIATES MARKET: BY END USER, 2021
FIGURE 38 NORTH AMERICA API INTERMEDIATES MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 39 NORTH AMERICA API INTERMEDIATES MARKET: BY END USER, CAGR (2021-2028)
FIGURE 40 NORTH AMERICA API INTERMEDIATES MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 NORTH AMERICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 42 NORTH AMERICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 43 NORTH AMERICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 44 NORTH AMERICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 NORTH AMERICA API INTERMEDIATES MARKET: SNAPSHOT (2020)
FIGURE 46 NORTH AMERICA API INTERMEDIATES MARKET: BY COUNTRY (2020)
FIGURE 47 NORTH AMERICA API INTERMEDIATES MARKET: BY COUNTRY (2021 & 2028)
FIGURE 48 NORTH AMERICA API INTERMEDIATES MARKET: BY COUNTRY (2020 & 2028)
FIGURE 49 NORTH AMERICA API INTERMEDIATES MARKET: BY TYPE (2021-2028)
FIGURE 50 NORTH AMERICA API INTERMEDIATES MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
